ABSTRACT
Introduction
The fatty acid composition of tissues and blood lipids is predominantly determined by dietary intake and endogenous metabolism, which is strongly genetically regulated (1-6). The 5 (D5D) and 6 (D6D) desaturases are encoded by the fatty acid desaturase (FADS) FADS1 and FADS2 genes, respectively. Both of these genes are located on chromosome 11 (11q12-13.1) and are the key enzymes in the synthesis pathway of longchain PUFAs (Figure 1) . Regulating fatty acid metabolism (2) (3) (4) (5) , polymorphisms in the FADS gene cluster also have an important impact on lipid profiles and glucose homeostasis (6) (7) (8) . The health benefits of substituting dietary long-chain PUFAs for SFAs are well known (9) , and many studies also support metabolic benefits of n-6 PUFAs, especially linoleic acid (LA; 18:2n-6) (9-13). Conversely, there are concerns related to endogenous conversion of LA to arachidonic acid (AA; 20:4n-6), which may lead to increased production of downstream proinflammatory and prothrombotic metabolites of AA (e.g., eicosanoids) (14) . Although it is important to study the effects of individual PUFAs on inflammation and metabolic diseases, there is also a need to better understand how the enzymes regulating fatty acid metabolism, and the genes coding them, influence this effect.
Many of the downstream products of PUFAs are lipid mediators with prominent roles in pro-and anti-inflammatory processes. This class of lipids arises from metabolism of n-6 and n-3 PUFAs by 1 of 3 major enzymatic pathways, cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP), or by nonenzymatic auto-oxidation ( Figure 1 ) (15) . Few studies have investigated how PUFA intake affects the overall lipid mediator profile, and studies conducted in humans are rare (16) (17) (18) (19) .
Genetic variation in FADS1 impacts not only the synthesis of AA but also the synthesis of 5-LOX products (20) . However, there are no data related to interactions between dietary intake of PUFAs and genetic variants related to long-chain PUFA metabolism and their possible link to low-grade inflammation.
The aim of this study was to investigate how the interaction of FADS1 rs174550 genotypes and LA proportions in plasma lipids associate with fasting glucose and low high-sensitivity C-reactive protein (hsCRP). In addition, we investigated how increased consumption of LA affects the fatty acid composition of plasma lipids (primary outcome), lipid mediator profiles, hsCRP, and fasting glucose in individuals with different genotypes (TT or CC) of FADS1 rs174550 polymorphism in a clinical trial. A common intron variant, rs174550, was selected as a marker for variation in the FADS1/2 locus, because it has been strongly associated with both serum fatty acids and fasting plasma glucose (8, 21) .
Methods

Subjects and study design
Metabolic Syndrome in Men cohort.
The Metabolic Syndrome in Men (METSIM) Study includes 10, 197 Finnish men, aged 45-73 y at baseline, randomly selected from the population register of the town of Kuopio, Eastern Finland, and examined in 2005-2010 (22) . The principal aim of the METSIM study is to investigate genetic and nongenetic factors associated with the risk of type 2 diabetes, cardiovascular disease, and cardiovascular disease risk factors in cross-sectional and longitudinal settings. This study includes a random sample of 1352 men with plasma fatty acids measured at baseline (23) , variant rs174550 genotyped, and hsCRP <15 mg/L.
FADSDIET intervention.
Altogether, 225 men from the METSIM study population were invited to participate in the FADSDIET intervention study FADS2 gene FIGURE 1 Simplified schematic overview of endogenous synthesis of long-chain PUFAs and synthesis of their downstream products via COX, LOX, CYP, and NE. In the absence of stereochemistry, it is not possible to discern the synthetic route of the mono-hydroxy fatty acids, and these compounds are accordingly listed in multiple pathways. AA, arachidonic acid; ALA, α-linolenic acid; COX, cyclooxygenase; CYP, cytochrome P450; DGLA, dihomo-γ -linolenic acid; DiHETE, dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHOME, dihydroxyoctadecenoic acid; EpETrE, epoxyeicosatrienoic acid; EpOME, epoxyoctadecenoic acid; FADS, fatty acid desaturase; HDoHE, hydroxydocosahexaenoic acid, HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxytetraenoic acid; HETrE, hydroxyeicosatrienoic acid; HOTrE, hydroxyoctadecatrienoic acid; KODE, oxo-octadecadienoic acid; LA, linoleic acid; LOX, lipoxygenase; NE, nonenzymatic auto-oxidation; PG, prostaglandin; TXB, thromboxane.
the Kuopio area and had BMIs (kg/m 2 ) of <30. Homozygote participants were invited in order to obtain the maximum difference in D5D activity between the genotype groups. Exclusion criteria were the use of anticoagulant treatment and severe chronic diseases. Altogether, 62 healthy men were allocated to the intervention, and 59 of them completed the study ( Figure  2 ). During the 4-wk run-in period, the diet was unchanged, but the participants discontinued consumption of fish oil or other oil supplements or lipid-lowering products (plant stanol or plant sterol-containing products), which were not allowed during the study. They completed a 4-d food record representing their baseline diet. Food records were completed in consecutive predefined days including 1 weekend day, and a clinical nutritionist checked the records upon return. Portion sizes were weighed or estimated using household measures and portionsize pictures. During the 4-wk intervention period, participants consumed their habitual diet with a supplement of 30, 40, or 50 mL (27-45 g) sunflower oil (62% of LA) daily depending on BMI. This supplement provided 17-28 g [6% of total energy (E%)] of LA daily on top of the mean intake of ∼10-12 g (4.5 E%). A 7-d food record (predefined consecutive days) was kept during the intervention period. Participants also recorded their daily consumption of sunflower oil throughout the study. The food records were analyzed by AivoDiet nutrient calculation software (version 2.0.2.1; Aivo Finland) based on national and international analyses and international food-composition tables. The study plan was approved by the Ethical Committee of the Hospital District of Northern Savo. The subjects received both oral and written information.
The FADS1 rs174550 variant has a high effect size on fatty acids. Therefore, it is possible to observe differences between genotypes with a relatively small sample size: for example, with 10 homozygotes participants/group, there is 95% power to observe significant differences between homozygote genotypes (TT compared with CC, α = 0.05) in AA (30% difference) based on cross-sectional data in the METSIM study. However, there were no earlier data on the genotype-specific responses to LA in intervention studies. Based on these assumptions, we estimated that a sample size of 30/group would provide sufficient statistical power.
Measurements
Genotyping.
The variant rs174550 (FADS1) was genotyped using the TaqMan SNP Genotyping Assay (Applied Biosystems) according to their protocol.
Biochemical analyses (lipids, glucose, insulin, hsCRP, fatty acids, and lipid mediator profiling).
Concentrations of serum total, LDL, and HDL cholesterol and total triglycerides were analyzed using commercial kits (981813, 981656, 981823, and 981786, respectively; Thermo Fisher Scientific) and the Konelab 20XTi Clinical Chemistry Analyzer (Thermo Fisher Scientific). The within-run variations (CV%) were 1.9-3.9% and the between-run CV% values were 1.8-3.6 for the lipids. Plasma glucose was analyzed using the Konelab 20XTi Clinical Chemistry Analyzer and Enzymatic photometric (glucose hexokinase) method (kit 981304; Thermo Fisher Scientific). Plasma insulin concentration was analyzed using a chemiluminometric immunoassay method (DiaSorin Liaison Analyzer; DiaSorin GmbH). The within-run variations for glucose and insulin were 2.7% and 3.7%, respectively, and the between-run variations were between 1.8-4.1% and 3.8-5.1%.
hsCRP was analyzed by enhanced immunoturbimetric assay using the Cobas 6000 automated analyzer (Hitachi High Technology Co.) and C-reactive Protein High Sensitive Assay reagent (Roche Diagnostics GmbH). The fatty acid composition of plasma lipid fractions was measured by gas chromatography, as previously described (24) . In brief, lipids were extracted from plasma samples using chloroform-methanol (2:1), and lipid fractions were separated with an aminopropyl column. Fatty acids in lipid fractions were transmethylated with 14% borontrifluoride in methanol. Finally, fatty acid methyl esters were analyzed by a 7890A gas chromatograph (Agilent Technologies, Inc.) equipped with a 25-m free fatty acid phase column (Agilent Technologies, Inc.). Cholesteryl nonadecanoate (Nu Chek Prep, Inc.), trinonadecanoin, and phosphatidylcholine dinonadecanoyl (Larodan Fine Chemicals) served as internal standards.
The within-run variation for AA in phospholipids was 0.85%, and the between-run variation was 1.17%. The corresponding CV% values in cholesteryl esters were 0.6% and 1.73%. D5D and D6D activities were estimated by the ratios of 20:4n-6 to 20:3n-6 and 18:3n-6 to 18:2n-6, respectively. Lipid mediator profiling was performed by liquid chromatography-mass spectrometry, as previously described (25) .
Statistical methods
Statistical analyses were performed using the IBM SPSS statistics software (version 23; IBM Corp.). Biochemical and statistical analyses were performed only for those individuals who had samples at baseline and after the intervention (n = 59; not intention to treat). The normality of the distributions of the variables was tested using a Kolmogorov-Smirnov normality test with Lilliefors significance correction. Variables with skewed distribution were transformed to base-10 logarithmic scale to achieve normal distribution. Nonparametric tests were used when a normal distribution was not achieved. Differences according to the LA tertiles within the genotypes were tested using 1-factor ANOVA. Interaction between genotypes (additive model) and LA proportion were tested using ANCOVA adjusted for LA, genotype, and their interaction. Differences in clinical characteristics and fatty acid distribution between the 3 genotypes were tested using ANOVA for normally distributed variables and a KruskalWallis test for skewed variables. Within-genotype comparisons (0 wk compared with 4 wk) were performed using a pairedsamples t test for normally distributed variables and a Wilcoxon signed rank test for skewed variables. The diet × genotype interaction was tested with a repeated-measures general linear model. Comparisons between the genotypes were performed using an independent-samples t test for normally distributed variables and a Mann-Whitney U test for skewed variables. The Pearson chi-square test was used to test differences by statin use between the genotypes. Fold changes were calculated by dividing endpoint values by baseline values. Correlation analyses were performed using Spearman's rank correlation. The Benjamini-Hochberg false-discovery rate was used to adjust general lipid mediator profiling results for multiple comparisons (24) . A false-discovery rate P value of <0.05 was considered significant among lipid mediators. False-discovery rate P values were calculated using R Project for Statistical Computing version 3.4.0 (R Foundation for Statistical Computing).
Results
Clinical characteristics and n-6 PUFAs according to FADS1 rs174550 genotype in the METSIM study
The clinical characteristics of the METSIM participants according to the genotypes of rs174550 of the FADS1 gene are shown in Table 1 . Clinical characteristics did not differ according to genotype, except for participants with the rs174550-TT genotype, who had a lower diastolic blood pressure (P = 0.034; Table 1 ). The proportions of n-6 PUFAs differed across the genotypes in all plasma lipid fractions ( Table 2) , as expected.
Interaction between proportion of plasma LA and rs174550 genotype in the METSIM study A higher content of LA in plasma phospholipids was associated with favorable clinical characteristics in the METSIM study, including lower fasting glucose and hsCRP (Supplemental Table 1 ). In participants with the rs174550-TT genotype, the concentration of fasting glucose was lower in the second and third LA tertiles, whereas in those with the CC genotype, there were no significant differences between the LA tertiles (genotype × LA interaction, P = 0.05; Figure 3 ).
Clinical characteristics, dietary intake, and compliance with the diet in the FADSDIET trial
In order to study the effect of increased consumption of LA in individuals with rs174550-CC or rs174550-TT genotypes of the FADS1 gene, we conducted a genotype-based trial (FADSDIET) with 59 participants recruited from the METSIM study. The clinical characteristics of the FADSDIET participants are shown in Table 3 . There were no significant differences in the clinical characteristics at baseline, except for participants in the CC genotype group who were older than those in the TT group (P < 0.001). Fasting glucose decreased significantly in participants with the CC genotype (P = 0.001) but did not change in participants with the TT genotype (diet × genotype interaction, P = 0.008; Table 3 ).
Based on daily records, the adherence to the consumption of sunflower oil was excellent. The mean consumption of sunflower oil was 30 and E%) increased during the intervention period ( Table 4) . There were no differences in dietary intake between genotypes. The mean intake of LA increased from a mean of 10 g to 31 g, similarly in both genotype groups (Table 4) .
n-6 PUFA composition of plasma lipids in the FADSDIET trial
The percentage changes in n-6 PUFA proportions and estimated D5D and D6D activities in plasma lipid fractions are shown in Figure 4 . There was a significant increase in the LA proportion in all lipid fractions in both genotype groups.
A significant interaction between intervention and genotype was observed in AA, the proportion of which decreased in participants with the CC genotype, but remained unchanged (in phospholipids) or decreased only slightly (in cholesteryl esters) in participants with the TT genotype. The results were similar with absolute concentrations (results not shown).
D5D and D6D activities
The estimated activities of both D5D and D6D were elevated in individuals with the TT genotype compared with individuals with the CC genotype at baseline and after the intervention in 
Fasting glucose concentration according to FADS1 rs174550 genotypes and tertiles of LA proportions in phospholipids in the METSIM population (n = 444 in TT, n = 648 in TC, and n = 245 in CC genotypes). Values are means (95% CIs). Differences according to LA tertiles within genotypes have been tested using 1-factor ANOVA. Interactions between genotypes (additive model) and LA proportions were tested using ANCOVA adjusted for LA, genotype, and their interaction. * * P < 0.01. FADS1, fatty acid desaturase 1; LA, linoleic acid; METSIM, Metabolic Syndrome in Men.
the FADSDIET study (Supplemental Figure 1) , as detailed in a previous publication (26) . The same findings were observed in the METSIM study (Table 2) .
Low-grade inflammation
In the METSIM population, participants with rs174550-TT or rs174550-TC genotypes had a lower hsCRP concentration in the tertile with the highest proportion of LA in phospholipids compared with the other LA tertiles, whereas this was not observed in carriers of the CC genotype (Supplemental Figure  2A) . However, there were no significant genotype × LA interactions. In the FADSDIET intervention, the response to higher LA intake in hsCRP was different between the genotypes. Following the high-LA diet, individuals with the rs174550-TT genotype had a trend toward decreased (P = 0.088) hsCRP, whereas individuals with the rs174550-CC genotype had a trend toward increased (P = 0.084) hsCRP (diet × genotype interaction, P < 0.05; Figure 5 ).
Lipid mediator concentrations
The distributions of lipid mediator concentrations according to their parent PUFAs are shown in Supplemental Figure 3 . The genotype affected concentrations of AA-derived lipid mediators (eicosanoids) belonging to various pathways, including LOX, COX, and CYP450 (Supplemental Table 2 ). Eicosanoid concentrations were higher in individuals with the TT genotype than in participants with the CC genotype, both at baseline and at the end of the intervention; however, only a few lipids changed during the intervention (Supplemental Figure 3 , Supplemental Table 2 ). As expected, increased consumption of LA in the FADSDIET intervention increased the concentrations of most of the LAderived lipid mediators in both genotype groups (Supplemental Table 2 ). After correction for multiple comparisons, there were no significant diet × genotype interactions. The results for the individual stereoisomers are shown in Supplemental Table 3 .
Lipid mediators to the PUFA ratios
Because results for absolute concentrations of lipid mediators were different from our hsCRP findings, we looked at the lipid mediator to phospholipid PUFA ratios in plasma to examine the relative levels of lipid mediators compared with their precursors PUFAs. Conversely, with the absolute levels, the relative levels of many eicosanoids were lower in the TT genotype group than in the CC genotype group at baseline and after the intervention (Supplemental Table 4 ). After correction for multiple comparisons, there were no significant diet × genotype interactions.
Correlations between lipid mediators, fatty acids, and hsCRP
The correlations between proportions of substrate PUFAs in plasma phospholipids and concentrations of plasma lipid mediators are shown in Figure 6 and Supplemental Figure 4 . As expected, LA-derived lipid mediators correlated positively with LA, and AA-derived lipid mediators correlated positively with AA. However, correlations between the AA proportion in the plasma phospholipids and eicosanoids in plasma were much stronger and only reached significance in the TT genotype. Correlations between lipid mediators and hsCRP were also strongly dependent on genotype. At baseline, many eicosanoids correlated positively with hsCRP in the TT genotype but not in participants with the CC genotype. Correlations between eicosanoids and hsCRP were lost at the end of the intervention. There were no direct correlations between AA proportion in phospholipids and hsCRP concentration in either genotype.
Discussion
Low-grade inflammation is an important factor in the progression of many chronic diseases such as type 2 diabetes and cardiovascular diseases (27, 28) . Low-grade inflammation could be affected by diet (29) , but the effect of the amount or quality of dietary fat has remained controversial (10, 30) . Based on our data, the discrepant findings could be partly related to a genetic variation in the FADS1 locus. We showed that besides regulation of proportions of PUFAs in plasma lipids, the FADS1 rs174550 genotype modified concentrations of inflammation-related lipid mediators. Furthermore, responses in concentrations of serum hsCRP and plasma fasting glucose differed between the genotype groups. In addition, correlations between lipid mediators and their substrate fatty acids as well as correlations between lipid mediators and plasma hsCRP concentrations in healthy men were modified by genotype.
As expected, increased intake of LA significantly elevated the plasma concentrations of many LA-derived lipid mediators in both genotypes. However, there were few observed changes in eicosanoid concentrations following the LA intervention. Recently, Leng et al. (19) showed in rats that increased dietary LA resulted in higher concentrations of AA and other n-6-derived lipid mediators in tissues such as kidney and liver. However, in γ γ γ FIGURE 4 Changes in proportions of n-6 PUFAs in plasma phospholipids (A) and cholesteryl esters (B) according to FADS1 rs174550 genotypes in the FADSDIET intervention. Values are mean (95% CI) percentages. The diet × genotype interaction was tested using a repeated-measures general linear model. There were significant diet × genotype interactions for arachidonic acid in phospholipids (P = 0.014) and arachidonic acid in cholesteryl esters (P = 0.003) and for estimated D5D activity in cholesteryl esters (P = 0.004). Within-genotype comparisons (0 wk compared with 4 wk) were performed using a paired-samples t test . * P < 0.05, * * P < 0.01, * * * P < 0.001. TT, n = 26; CC, n = 33. D5D, 5 desaturase; D6D, 6 desaturase; FADS1, fatty acid desaturase 1. agreement with our findings, only LA-derived lipid mediators were increased in serum. The effect of the FADS1 genotype upon fatty acid and lipid mediator profiles in other tissues in humans remains to be elucidated.
L
FIGURE 5
Mean (95% CI) concentrations of hsCRP (n = 26 in TT, n = 33 in CC) at baseline and after the 4-wk high-LA diet according to rs174550 genotypes in the FADSDIET intervention. The diet × genotype interaction was tested using a repeated-measures general linear model. There was a significant diet × genotype interaction (P = 0.026). hsCRP, highsensitivity C-reactive protein.
Recent findings in Fads1 knockdown mice showed promotion of hepatic inflammation, especially following supplementation of substrate fatty acids for long-chain PUFA biosynthesis (31). In those mice for which n-3 substrate fatty acids were provided, the findings were in line with our observation of increased hsCRP in the participants with decreased D5D and D6D activities (individuals with the CC allele) during the high-LA intervention. It is noteworthy that inflammation seems not to be mediated by increased AA concentration, because AA concentration was decreased during the intervention both in Fads1 knockdown mice and in participants of the present intervention with a genotype related to decreased D5D activity. Furthermore, despite increased hepatic inflammation, FADS1 knockdown mice had improvements in glucose tolerance (31) , similar to our findings of significantly decreased fasting glucose concentration in the CC genotype compared with the TT genotype. The FADS1 rs174550 genotype has previously been linked to fasting glucose, but there are no previous studies in humans showing diet × genotype interactions regarding this SNP and glucose metabolism.
It has been suggested that the association between PUFAs and inflammation is mediated by anti-and proinflammatory lipid mediators such as eicosanoids (5) . In our study, lipid mediator profiling did not reveal a simple explanation for the genotype-specific response in hsCRP. However, we found that the 
FIGURE 6
Spearman rank correlations between the fatty acid substrates and lipid mediators and hsCRP at baseline and at the end of the intervention in the FADSDIET study (P < 0.05). AA, arachidonic acid; COX, cyclooxygenase; CYP450/CYP, cytochrome P450; DiHETrE, dihydroxyeicosatrienoic acid; DiHOME, dihydroxyoctadecenoic acid; EpETrE, epoxyeicosatrienoic acid; EpOME, epoxyoctadecenoic acid; EKODE, epoxyketo-octadecenoic acid; EpODE, Epoxyoctadecadienoic acid; HETE, hydroxytetraenoic acid; hsCRP, high-sensitivity C-reactive protein; HODE, hydroxyoctadecadienoic acid; HHTrE, hydroxy-heptadecatrienoic acid; iPF2a-VI, Isoprostane F2a-VI; KETE, ketoeicosatetraenoic acid; KODE, oxo-octadecadienoic acid; LA, linoleic acid; LOX, lipoxygenase; NE, nonenzymatic auto-oxidation; PGE, prostaglandin E; PGF2a, prostaglandin F2a; sEH, soluble epoxide hydrolase; TriHOME, trihydroxyoctadecenoic acid; TXB, thromboxane. correlation between eicosanoids and hsCRP is modified by the FADS1 genotype, further strengthening the conclusion that the genotype modifies the interaction between diet and inflammation. In future studies, it would be important to also investigate FADS1 genotype-specific effects on n-3 fatty acid interventions, because in real life, the diet is always a combination of both n-3 and n-6 fatty acids, and there is competition with the same enzymes both in long-chain PUFAs (32) and in lipid mediator synthesis pathways (33) (34) (35) . The regulation of lipid mediator biosynthesis is known to be complex. In in vitro analyses, the selectivity for formation of CYP products of n-3 over n-6 PUFAs has been shown (35) , whereas the opposite selectivity has been shown in other studies of LOX and COX enzymes (33, 34) . It was recently shown in mice that Fads1 is an important regulator of inflammation initiation and resolution, and endogenous and exogenous (dietary) n-3 and n-6 fatty acids are key determinants of inflammatory disease progression (31) . The FADS1 rs174550 genotype has not been previously linked to hsCRP, although few other FADS variants have been associated with CRP (5, 36) . Interestingly, hsCRP concentration did not differ among the genotypes in our cross-sectional data, but the response to a high-LA diet was genotype specific.
The relatively small sample size could be considered a limitation in our clinical intervention. However, the study design is unique and powerful due to the genotype-based recruitment of individuals matched for sex and BMI. Furthermore, the FADS1 rs174550 variant has a high effect size on fatty acid concentrations, and so it was possible to observe differences between genotypes with this sample size exceeding power calculations. In this study, a common variant, rs174550, associated with PUFA concentrations and fasting glucose was selected as a marker for variation in the FADS1/2 locus (8, 21) . In this type of candidate gene-based intervention, only a single SNP could be considered. A more complex approach that takes into consideration an additive model of FADS SNPs or FADS haplotypes could have shown stronger effects (36) . However, from a practical point of view, the selection of participants from a population based on a longer haplotype would be extremely challenging.
Another limitation of the study is that we were able to determine changes only in plasma. We were not able to measure tissue concentrations of PUFAs in this study, and it is possible that changes in tissue concentrations could explain the missing link between the proportions of fatty acids and the concentration of hsCRP. Our earlier findings suggest that there seems to be a complex interaction, partly regulated by the FADS genotype, regulating the interactions between fatty acids in adipose tissue and inflammation in the liver (37) . Based on food records, energy intake was significantly increased during the intervention period, which could be considered a third limitation. However, there were no changes in body weight or BMI, and an increase in energy intake was similar in both genotype groups. It is likely that the increased energy intake was at least partly related to the fact that oil consumption was carefully recorded during the intervention period. Energy intake should in any case be considered, especially in longer interventions. A major strength of this study is that we were able to combine data from both cross-sectional and intervention studies. However, because both studies were performed in middle-aged and older men, these results cannot be generalized to women or the younger population, for example.
In conclusion, the FADS1 genotype modifies the lipid mediator profile and inflammatory responses to an LA-rich diet. This is a new concept warranting further randomized trials in individuals with specific genotypes to demonstrate potentially divergent effects of diets with modified fatty acid content. It remains to be elucidated if it would be beneficial to have genotype-based modifications in recommendations for the intake of LA and possibly also for n-3 fatty acids.
